Immuron Limited (ASX:IMC)

Market Cap	11.39M
Revenue (ttm)	7.29M +48.6%
Net Income	-5.22M
EPS	-0.02
Shares Out	325.51M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	38,211
Average Volume	644,752
Open	0.0360
Previous Close	0.0350
Day's Range	0.0350 - 0.0360
52-Week Range	0.0340 - 0.0980
Beta	0.52
RSI	39.59
Earnings Date	Feb 27, 2026

About Immuron

Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers’ diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for digestive tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive func...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1994
• Employees: 7
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: IMC

Financial Performance

In 2025, Immuron's revenue was 7.29 million, an increase of 48.63% compared to the previous year's 4.90 million. Losses were -5.22 million, -24.81% less than in 2024.